Key facts
- This page summarizes Christopher B. Ehrlich's Form 4 filing for eFFECTOR Therapeutics, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 13 Jun 2024, 18:25.
Christopher B. Ehrlich - 13 Jun 2024 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 13 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Jun 2024, 18:25:33 UTC
- Prior SEC filing
- 27 Mar 2024
- Next SEC filing
- 11 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Byrnes, Attorney-in-Fact for Christopher B. Ehrlich
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher B. Ehrlich filed Form 4 for eFFECTOR Therapeutics, Inc. on 13 Jun 2024.
Change
- Previous filing in this sequence was filed on 27 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EFTR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +800
- Change %
- Price
- $0.000000
- Shares after
- 800
- Date
- 13 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 800
- Exercise price
- $1.38
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest in full on the earlier to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date.